Q4FY21 Result Update - Cadila Healthcare - ICICI Direct

Q4 revenues grew 2.5% YoY to Rs. 3847 crore. Domestic formulations grew 14.7% YoY to Rs. 1023 crore. US sales fell 14.3% YoY to Rs. 1509 crore. Wellness segment grew a robust 22.1% YoY to Rs. 598 crore. Emerging markets grew 45.5% YoY to Rs. 250 crore. API segment grew 19.9% YoY to Rs. 140 crore. Animal health segment grew 25.2% YoY to Rs. 150 crore. EBITDA margins expanded 115 bps YoY to 22.2% mainly due to lower other expenditure partly offset by lower gross margins. Subsequently, EBITDA grew 8.1% YoY to Rs. 855 crore. Reported PAT grew 73.3% YoY to Rs. 679 crore. Delta vis-à-vis EBITDA was mainly due to DTA related adjustments taken in the quarter.

For details, click on the link below: Link to the report

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.618.5 as compared to the previous close of Rs. 621.25. The total number of shares traded during the day was 205182 in over 5279 trades.

The stock hit an intraday high of Rs. 623.85 and intraday low of 611.8. The net turnover during the day was Rs. 126551509.

Source : Equity Bulls

Keywords